

Theodore E Warkentin

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6246133/publications.pdf>

Version: 2024-02-01

378
papers

35,528
citations

2963

93
h-index

3714

179
g-index

394
all docs

394
docs citations

394
times ranked

14602
citing authors

#	ARTICLE	IF	CITATIONS
1	Recognizing Vaccine-Induced Immune Thrombotic Thrombocytopenia. <i>Critical Care Medicine</i> , 2022, 50, e80-e86.	0.4	30
2	Vaccine-induced immune thrombotic thrombocytopenia (VITT): Update on diagnosis and management considering different resources. <i>Journal of Thrombosis and Haemostasis</i> , 2022, 20, 149-156.	1.9	76
3	Heterogeneity of Vaccine-Induced Immune Thrombotic Thrombocytopenia after ChAdOx1 nCoV-19 Vaccination and Safety of Second Vaccination with BNT162b2. <i>Thrombosis and Haemostasis</i> , 2022, 122, 304-307.	1.8	11
4	Therapeutic strategies in patients with coagulopathy and disseminated intravascular coagulation: awareness of the phase-dependent characteristics. <i>Minerva Medica</i> , 2022, 112, .	0.3	7
5	The Epidemiology of Thrombosis With Thrombocytopenia Syndrome: Analogies With Heparin-Induced Thrombocytopenia. <i>Annals of Internal Medicine</i> , 2022, 175, 604-605.	2.0	6
6	Vaccine-induced immune thrombotic thrombocytopenia (VITT) – update on diagnosis and management considering different resources: Response to Comment from Yamada et al. <i>Journal of Thrombosis and Haemostasis</i> , 2022, 20, 542-543.	1.9	8
7	Platelet-activating anti-PF4 disorders: An overview. <i>Seminars in Hematology</i> , 2022, 59, 59-71.	1.8	25
8	Laboratory testing for VITT antibodies. <i>Seminars in Hematology</i> , 2022, 59, 80-88.	1.8	11
9	Acute thrombocytopenia suggesting thrombotic microangiopathy. <i>American Journal of Hematology</i> , 2022, 97, 659-665.	2.0	1
10	<i>ABO</i> O blood group as a risk factor for platelet reactivity in heparin-induced thrombocytopenia. <i>Blood</i> , 2022, 140, 274-284.	0.6	9
11	Treatment of vaccine-induced immune thrombotic thrombocytopenia (VITT). <i>Seminars in Hematology</i> , 2022, 59, 89-96.	1.8	31
12	Vaccine-induced immune thrombotic thrombocytopenia (VITT). <i>Seminars in Hematology</i> , 2022, 59, 57-58.	1.8	7
13	Platelet-activating anti-PF4 antibodies mimic VITT antibodies in an unvaccinated patient with monoclonal gammopathy. <i>Haematologica</i> , 2022, 107, 1219-1221.	1.7	28
14	How to dose and monitor argatroban for treatment of <sc>HIT</sc>. <i>British Journal of Haematology</i> , 2022, 197, 653-655.	1.2	1
15	Genome-wide association study of platelet factor 4/heparin antibodies in heparin-induced thrombocytopenia. <i>Blood Advances</i> , 2022, 6, 4137-4146.	2.5	7
16	SARS-CoV-2 Infection in Patients with a History of VITT. <i>New England Journal of Medicine</i> , 2022, 387, 88-90.	13.9	7
17	Cerebral venous sinus thrombosis associated with spontaneous heparin-induced thrombocytopenia syndrome after total knee arthroplasty. <i>Platelets</i> , 2021, 32, 936-940.	1.1	42
18	Spontaneous Heparin-Induced Thrombocytopenia Presenting as Cerebral Venous Sinus Thrombosis. <i>Neurology: Clinical Practice</i> , 2021, 11, e929-e931.	0.8	17

#	ARTICLE	IF	CITATIONS
19	A comparative study of platelet factor 4â€enhanced platelet activation assays for the diagnosis of heparinâ€induced thrombocytopenia. <i>Journal of Thrombosis and Haemostasis</i> , 2021, 19, 1096-1102.	1.9	10
20	Managing thrombosis and cardiovascular complications of COVID-19: answering the questions in COVID-19-associated coagulopathy. <i>Expert Review of Respiratory Medicine</i> , 2021, 15, 1003-1011.	1.0	12
21	Heparin-induced thrombocytopenia. <i>Cmaj</i> , 2021, 193, E736-E736.	0.9	29
22	Symmetrical peripheral gangrene in critical illness. <i>Transfusion and Apheresis Science</i> , 2021, 60, 103094.	0.5	12
23	Post-cardiac surgery thrombotic thrombocytopenic purpura: presence of anti-ADAMTS13 autoantibodies at preoperative baseline. <i>Platelets</i> , 2021, , 1-5.	1.1	1
24	Frequency of positive anti-PF4/polyanion antibody tests after COVID-19 vaccination with ChAdOx1 nCoV-19 and BNT162b2. <i>Blood</i> , 2021, 138, 299-303.	0.6	125
25	Thrombotic Thrombocytopenia after ChAdOx1 nCov-19 Vaccination. <i>New England Journal of Medicine</i> , 2021, 384, 2092-2101.	13.9	1,765
26	Anemia-Induced Bleeding in Patients with Platelet Disorders. <i>Transfusion Medicine Reviews</i> , 2021, 35, 22-28.	0.9	6
27	Antiâ€platelet factor 4 antibodies causing VITT do not cross-react with SARS-CoV-2 spike protein. <i>Blood</i> , 2021, 138, 1269-1277.	0.6	102
28	Spontaneous HIT syndrome: Knee replacement, infection, and parallels with vaccine-induced immune thrombotic thrombocytopenia. <i>Thrombosis Research</i> , 2021, 204, 40-51.	0.8	72
29	Heparin-Induced Thrombocytopenia and Vaccine-Induced Immune Thrombotic Thrombocytopenia Antibodies: Fraternalâ€Not Identicalâ€Twins. <i>Thrombosis and Haemostasis</i> , 2021, 121, 1558-1561.	1.8	5
30	Venous Thromboembolism and Mild Thrombocytopenia after ChAdOx1 nCoV-19 Vaccination. <i>Thrombosis and Haemostasis</i> , 2021, 121, 1677-1680.	1.8	22
31	Adjunct Immune Globulin for Vaccine-Induced Immune Thrombotic Thrombocytopenia. <i>New England Journal of Medicine</i> , 2021, 385, 720-728.	13.9	156
32	Insights in ChAdOx1 nCoV-19 vaccine-induced immune thrombotic thrombocytopenia. <i>Blood</i> , 2021, 138, 2256-2268.	0.6	228
33	Pitfalls in Diagnosing Vaccine-Induced Immune Thrombotic Thrombocytopenia. <i>Critical Care Medicine</i> , 2021, Publish Ahead of Print, .	0.4	0
34	Double high-dose immunoglobulin for ChAdOx1 nCov-19 vaccine-induced immune thrombotic thrombocytopenia. <i>Thrombosis Research</i> , 2021, 206, 14-17.	0.8	5
35	Heparin induced thrombocytopenia in relation to SARS-CoV-2 infection and ABO blood group. <i>Thrombosis Research</i> , 2021, 207, 62-65.	0.8	1
36	Proposal of the Definition for COVID-19-Associated Coagulopathy. <i>Journal of Clinical Medicine</i> , 2021, 10, 191.	1.0	83

#	ARTICLE	IF	CITATIONS
37	Serotoninâ€release assayâ€positive but platelet factor 4â€dependent enzymeâ€immunoassay negative: HIT or not HIT ?. American Journal of Hematology, 2021, 96, 320-329.	2.0	11
38	Editorial on Thaler et al. long-term follow-up after successful treatment of vaccine-induced prothrombotic immune thrombocytopenia. Thromb Res 2021 in press. Thrombosis Research, 2021, 207, 158-160.	0.8	1
39	Fondaparinux cross-reactivity in heparin-induced thrombocytopenia successfully treated with high-dose intravenous immunoglobulin and rivaroxaban. Platelets, 2020, 31, 124-127.	1.1	16
40	Serotoninâ€release assayâ€negative heparinâ€induced thrombocytopenia. American Journal of Hematology, 2020, 95, 38-47.	2.0	43
41	Colloid Transfusion, Natural Anticoagulant Depletion, and Symmetric Peripheral Gangrene. New England Journal of Medicine, 2020, 383, 1592-1594.	13.9	3
42	Limitations of the particle immunofiltration assay test for diagnosis of heparinâ€induced thrombocytopenia. American Journal of Hematology, 2020, 95, E250-E254.	2.0	1
43	COVID-19 versus HIT hypercoagulability. Thrombosis Research, 2020, 196, 38-51.	0.8	37
44	ISTH DIC subcommittee communication on anticoagulation in COVIDâ€19. Journal of Thrombosis and Haemostasis, 2020, 18, 2138-2144.	1.9	69
45	Catastrophic antiphospholipid syndrome refractory to high-dose intravenous immunoglobulin responsive to therapeutic plasma exchange. Platelets, 2020, 32, 1-4.	1.1	5
46	Management of heparin-induced thrombocytopenia: systematic reviews and meta-analyses. Blood Advances, 2020, 4, 5184-5193.	2.5	11
47	Challenges in Detecting Clinically Relevant Heparin-Induced Thrombocytopenia Antibodies. Hamostaseologie, 2020, 40, 472-484.	0.9	11
48	Highâ€dose IVIG plus cangrelor platelet â€œanesthesiaâ€during urgent heparinâ€CPB in a patient with recent SRAâ€negative HITâ€thrombosis with persisting plateletâ€activating antibodies. Research and Practice in Thrombosis and Haemostasis, 2020, 4, 1060-1064.	1.0	14
49	Maximum 24â€hour platelet count fall: Metric for improving the diagnosis of heparinâ€induced thrombocytopenia among patients with intermediate probability 4Ts scores. Journal of Thrombosis and Haemostasis, 2020, 18, 2018-2024.	1.9	7
50	RE: The prothrombin time ratio is not a more effective marker for evaluating sepsisâ€induced coagulopathy than fibrinâ€related markers: Response to the Letterâ€toâ€theâ€Editor by Dr Wada. Journal of Thrombosis and Haemostasis, 2020, 18, 1507-1509.	1.9	1
51	The unique characteristics of COVID-19 coagulopathy. Critical Care, 2020, 24, 360.	2.5	366
52	Combination of two complementary automated rapid assays for diagnosis of heparinâ€induced thrombocytopenia (HIT). Journal of Thrombosis and Haemostasis, 2020, 18, 1435-1446.	1.9	23
53	Venous limb gangrene and pulseless electrical activity (PEA) cardiac arrest during management of deepâ€vein thrombosis and progressive limb ischemic necrosis following vascular surgery. American Journal of Hematology, 2020, 95, 712-717.	2.0	3
54	HIT: still stringing us along. Blood, 2020, 135, 1193-1194.	0.6	5

#	ARTICLE	IF	CITATIONS
55	A practical approach to evaluating postoperative thrombocytopenia. <i>Blood Advances</i> , 2020, 4, 776-783.	2.5	24
56	Ischemic limb necrosis in septic shock: What is the role of high-dose vasopressor therapy?. <i>Journal of Thrombosis and Haemostasis</i> , 2019, 17, 1973-1978.	1.9	17
57	High-dose intravenous immunoglobulin for the treatment and prevention of heparin-induced thrombocytopenia: a review. <i>Expert Review of Hematology</i> , 2019, 12, 685-698.	1.0	121
58	Diagnosis and management of sepsis-induced coagulopathy and disseminated intravascular coagulation. <i>Journal of Thrombosis and Haemostasis</i> , 2019, 17, 1989-1994.	1.9	325
59	Microvascular Thrombosis and Ischaemic Limb Losses in Critically Ill Patients. <i>Hamostaseologie</i> , 2019, 39, 006-019.	0.9	19
60	Advance in the Management of Sepsis-Induced Coagulopathy and Disseminated Intravascular Coagulation. <i>Journal of Clinical Medicine</i> , 2019, 8, 728.	1.0	128
61	Proposal of a two-step process for the diagnosis of sepsis-induced disseminated intravascular coagulation. <i>Journal of Thrombosis and Haemostasis</i> , 2019, 17, 1265-1268.	1.9	37
62	Timeline of heparin-induced thrombocytopenia seroconversion in serial plasma samples tested using an automated latex immunoturbidimetric assay. <i>International Journal of Laboratory Hematology</i> , 2019, 41, 493-502.	0.7	12
63	Laboratory diagnosis of heparin-induced thrombocytopenia. <i>International Journal of Laboratory Hematology</i> , 2019, 41, 15-25.	0.7	84
64	Neutrophil and Monocyte Counts in Heparin-Induced Thrombocytopenia. <i>Thrombosis and Haemostasis</i> , 2019, 119, 941-951.	1.8	9
65	Autoimmune heparin-induced thrombocytopenia and venous limb gangrene after aortic dissection repair: in vitro and in vivo effects of intravenous immunoglobulin. <i>Transfusion</i> , 2019, 59, 1924-1933.	0.8	22
66	The association between platelet transfusions and mortality in patients with critical illness. <i>Transfusion</i> , 2019, 59, 1962-1970.	0.8	11
67	High-dose intravenous immunoglobulin to treat spontaneous heparin-induced thrombocytopenia syndrome. <i>Journal of Thrombosis and Haemostasis</i> , 2019, 17, 841-844.	1.9	40
68	Spontaneous heparin-induced thrombocytopenia syndrome presenting as bilateral adrenal infarction after knee arthroplasty. <i>BMJ Case Reports</i> , 2019, 12, e232769.	0.2	9
69	Fibronectin modulates formation of PF4/heparin complexes and is a potential factor for reducing risk of developing HIT. <i>Blood</i> , 2019, 133, 978-989.	0.6	14
70	Differential diagnoses for sepsis-induced disseminated intravascular coagulation: communication from the SSC of the ISTH. <i>Journal of Thrombosis and Haemostasis</i> , 2019, 17, 415-419.	1.9	50
71	An international external quality assessment for laboratory diagnosis of heparin-induced thrombocytopenia. <i>Journal of Thrombosis and Haemostasis</i> , 2019, 17, 525-531.	1.9	23
72	Acquired Thrombocytopenia. , 2019, , 135-148.		0

#	ARTICLE	IF	CITATIONS
73	If the Platelets Are Low, Is It HIT?. Difficult Decisions in Surgery: an Evidence-based Approach, 2019, , 455-479.	0.0	0
74	Acute haemolysis, DIC and renal failure after transfusion of uncrossâ€mated blood during trauma resuscitation: illustrative case and literature review. Transfusion Medicine, 2018, 28, 319-325.	0.5	10
75	Symmetrical Peripheral Gangrene: Mechanisms for Limb Loss in the ICU in Patients With Retained Pulses. Clinical Pulmonary Medicine, 2018, 25, 61-66.	0.3	7
76	Platelet-Activating Antibodies Are Detectable at the Earliest Onset of Heparin-Induced Thrombocytopenia, With Implications for the Operating Characteristics of the Serotonin-Release Assay. Chest, 2018, 153, 1396-1404.	0.4	16
77	Cellular immune responses to platelet factor 4 and heparin complexes in patients with heparinâ€induced thrombocytopenia. Journal of Thrombosis and Haemostasis, 2018, 16, 1402-1412.	1.9	8
78	Levofloxacin-Induced Acute Immune-Mediated Thrombocytopenia of Rapid-Onset. Journal of Pharmacy Practice, 2018, 31, 234-237.	0.5	5
79	American Society of Hematology 2018 guidelines for management of venous thromboembolism: heparin-induced thrombocytopenia. Blood Advances, 2018, 2, 3360-3392.	2.5	448
80	Natural, not immune; classical, not alternative. Blood, 2018, 132, 2421-2422.	0.6	0
81	Concurrence of symmetrical peripheral gangrene and venous limb gangrene following polytrauma: a case report. Journal of Medical Case Reports, 2018, 12, 131.	0.4	6
82	Neutropenia and monocytopenia in recurrent anaphylactoid reactions after red blood cell transfusions in a woman with immunoglobulin A (IgA) deficiency and antiâ€IgA. Transfusion, 2018, 58, 2320-2325.	0.8	2
83	High sensitivity and specificity of an automated IgG-specific chemiluminescence immunoassay for diagnosis of HIT. Blood, 2018, 132, 1345-1349.	0.6	44
84	Thrombocytopenia Caused by Platelet Destruction, Hypersplenism, or Hemodilution. , 2018, , 1955-1972.		4
85	Intravenous Immune Globulin to Prevent Heparin-Induced Thrombocytopenia. New England Journal of Medicine, 2018, 378, 1845-1848.	13.9	37
86	Systematic review of fondaparinux for heparinâ€induced thrombocytopenia: When there are no randomized controlled trials. Research and Practice in Thrombosis and Haemostasis, 2018, 2, 678-683.	1.0	29
87	Heparinâ€induced thrombocytopeniaâ€associated thrombosis: from arterial to venous to venous limb gangrene. Journal of Thrombosis and Haemostasis, 2018, 16, 2128-2132.	1.9	16
88	Diagnostic accuracy of IgGâ€specific versus polyspecific enzymeâ€linked immunoassays in heparinâ€induced thrombocytopenia: a systematic review and metaâ€analysis. Journal of Thrombosis and Haemostasis, 2017, 15, 1203-1212.	1.9	32
89	Clinical effectiveness of a Bayesian algorithm for the diagnosis and management of heparinâ€induced thrombocytopenia. Journal of Thrombosis and Haemostasis, 2017, 15, 1640-1645.	1.9	15
90	Performance characteristics of an automated latex immunoturbidimetric assay [HemosIL Â® HIT-Ab (PF4-H)] for the diagnosis of immune heparin-induced thrombocytopenia. Thrombosis Research, 2017, 153, 108-117.	0.8	56

#	ARTICLE	IF	CITATIONS
91	Sepsis and persisting neutropenia in a drug addict. <i>American Journal of Hematology</i> , 2017, 92, 312-316.	2.0	1
92	How do we approach thrombocytopenia in critically ill patients?. <i>British Journal of Haematology</i> , 2017, 177, 27-38.	1.2	83
93	Red blood cell storage and in-hospital mortality: a secondary analysis of the INFORM randomised controlled trial. <i>Lancet Haematology</i> , 2017, 4, e544-e552.	2.2	34
94	Autoimmune HIT due to apheresis catheter heparin flushes for stem cell harvesting before autotransplantation for myeloma. <i>Blood</i> , 2017, 130, 1679-1682.	0.6	32
95	Autoimmune heparin-induced thrombocytopenia. <i>Journal of Thrombosis and Haemostasis</i> , 2017, 15, 2099-2114.	1.9	319
96	Spontaneous HIT syndrome post-knee replacement surgery with delayed recovery of thrombocytopenia: a case report and literature review. <i>Platelets</i> , 2017, 28, 614-620.	1.1	51
97	IV Immunoglobulin for Autoimmune Heparin-Induced Thrombocytopenia. <i>Chest</i> , 2017, 152, 453-455.	0.4	9
98	Fondaparinux for Treatment of Heparin-Induced Thrombocytopenia. <i>Journal of the American College of Cardiology</i> , 2017, 70, 2649-2651.	1.2	11
99	Direct oral anticoagulants for treatment of HIT: update of Hamilton experience and literature review. <i>Blood</i> , 2017, 130, 1104-1113.	0.6	152
100	Platelet count recovery and seroreversion in immune HIT despite continuation of heparin: further observations and literature review. <i>Thrombosis and Haemostasis</i> , 2017, 117, 1868-1874.	1.8	12
101	Apixaban for treatment of confirmed heparin-induced thrombocytopenia: a case report and review of literature. <i>Experimental Hematology and Oncology</i> , 2017, 6, 21.	2.0	12
102	Heparin-induced thrombocytopenia in 2017 and beyond. <i>Thrombosis and Haemostasis</i> , 2016, 116, 781-782.	1.8	5
103	Safe bridging to warfarin in heparin-induced thrombocytopenia. <i>Thrombosis Research</i> , 2016, 144, 226-228.	0.8	0
104	Rivaroxaban for treatment of suspected or confirmed heparin-induced thrombocytopenia study. <i>Journal of Thrombosis and Haemostasis</i> , 2016, 14, 1206-1210.	1.9	74
105	Demand on-demand testing for the diagnosis of heparin-induced thrombocytopenia. <i>Thrombosis Research</i> , 2016, 140, 163-164.	0.8	10
106	Knee replacement and HIT without heparin. <i>Blood</i> , 2016, 127, 961-962.	0.6	5
107	How I treat patients with a history of heparin-induced thrombocytopenia. <i>Blood</i> , 2016, 128, 348-359.	0.6	56
108	Shock, acute disseminated intravascular coagulation, and microvascular thrombosis: is "shock liver" the unrecognized provocateur of ischemic limb necrosis: reply. <i>Journal of Thrombosis and Haemostasis</i> , 2016, 14, 2317-2319.	1.9	2

#	ARTICLE	IF	CITATIONS
109	Platelet Activation Testing for Heparin-Induced Thrombocytopenia Antibodies. <i>Chest</i> , 2016, 150, 478-480.	0.4	3
110	Acute intraoperative HIT during heart surgery: Why so rare?. <i>Thrombosis Research</i> , 2016, 146, 110-112.	0.8	7
111	Letter of response to Peters and Vlaar commentary. <i>Transfusion</i> , 2016, 56, 2395-2397.	0.8	1
112	Management of immune-mediated thrombocytopenia. , 2016, , 245-264.		0
113	Protamine (heparin)-induced thrombocytopenia: a review of the serological and clinical features associated with anti-protamine/heparin antibodies. <i>Journal of Thrombosis and Haemostasis</i> , 2016, 14, 1685-1695.	1.9	25
114	B cells, PF4/heparin complexes, and complement. <i>Blood</i> , 2016, 128, 1781-1782.	0.6	2
115	Effect of Short-Term vs. Long-Term Blood Storage on Mortality after Transfusion. <i>New England Journal of Medicine</i> , 2016, 375, 1937-1945.	13.9	278
116	Clinical picture of heparin-induced thrombocytopenia (HIT) and its differentiation from non-HIT thrombocytopenia. <i>Thrombosis and Haemostasis</i> , 2016, 116, 813-822.	1.8	69
117	Management of heparin-induced thrombocytopenia. <i>Current Opinion in Hematology</i> , 2016, 23, 462-470.	1.2	36
118	Difficulties in establishing the diagnosis of immune thrombocytopenia: An agreement study. <i>American Journal of Hematology</i> , 2016, 91, E327-9.	2.0	22
119	Shock, acute disseminated intravascular coagulation, and microvascular thrombosis: is "shock liver" the unrecognized provateur of ischemic limb necrosis?. <i>Journal of Thrombosis and Haemostasis</i> , 2016, 14, 231-235.	1.9	21
120	Rationale and Design of the Informing Fresh versus Old Red Cell Management (INFORM) Trial: An International Pragmatic Randomized Trial. <i>Transfusion Medicine Reviews</i> , 2016, 30, 25-29.	0.9	15
121	Thrombin generation, ProC(®)Global, prothrombin time and activated partial thromboplastin time in thawed plasma stored for seven days and after methylene blue/light pathogen inactivation. <i>Blood Transfusion</i> , 2016, 14, 66-72.	0.3	7
122	The transfusion-related acute lung injury controversy: lessons from heparin-induced thrombocytopenia. <i>Transfusion</i> , 2015, 55, 1128-1134.	0.8	11
123	The Role for Optical Density in Heparin-Induced Thrombocytopenia. <i>Chest</i> , 2015, 148, 55-61.	0.4	42
124	Plasma exchange to remove HIT antibodies: dissociation between enzyme-immunoassay and platelet activation test reactivities. <i>Blood</i> , 2015, 125, 195-198.	0.6	78
125	Combination of 4Ts score and PF4/H-PaGIA for diagnosis and management of heparin-induced thrombocytopenia: prospective cohort study. <i>Blood</i> , 2015, 126, 597-603.	0.6	101
126	Scoring systems for heparin-induced thrombocytopenia (HIT): Whither now?. <i>Thrombosis and Haemostasis</i> , 2015, 113, 437-438.	1.8	10

#	ARTICLE	IF	CITATIONS
127	Distinguishing between anti-platelet factor 4/heparin antibodies that can and cannot cause heparin-induced thrombocytopenia. <i>Journal of Thrombosis and Haemostasis</i> , 2015, 13, 1900-1907.	1.9	78
128	Non-injection-site necrotic skin lesions complicating postoperative heparin thromboprophylaxis. <i>American Journal of Hematology</i> , 2015, 90, 747-750.	2.0	15
129	Heparin-induced thrombocytopenia. <i>Current Opinion in Critical Care</i> , 2015, 21, 576-585.	1.6	47
130	Warfarin-induced venous limb ischemia/gangrene complicating cancer: a novel and clinically distinct syndrome. <i>Blood</i> , 2015, 126, 486-493.	0.6	39
131	Ischemic Limb Gangrene with Pulses. <i>New England Journal of Medicine</i> , 2015, 373, 2385-2388.	13.9	11
132	Progressive, Fatal Thrombosis Associated With Heparin-Induced Thrombocytopenia After Cardiac Surgery Despite Therapeutic Anticoagulation With Argatroban: Potential Role for PTT and ACT Confounding. <i>Journal of Cardiothoracic and Vascular Anesthesia</i> , 2015, 29, 1319-1321.	0.6	13
133	Heparin-Induced Thrombocytopenia Presenting as Bilateral Adrenal Hemorrhages. <i>New England Journal of Medicine</i> , 2015, 372, 492-494.	13.9	52
134	Heparin-Induced Thrombocytopenia in Critically Ill Patients. <i>Seminars in Thrombosis and Hemostasis</i> , 2015, 41, 049-060.	1.5	87
135	4Ts scoring with hemofiltration or hemodialysis clotting. <i>Journal of Clinical Monitoring and Computing</i> , 2015, 29, 7-9.	0.7	7
136	Prevalence and clinical implications of anti-PF4/heparin antibodies in intensive care patients: a prospective observational study. <i>Journal of Thrombosis and Thrombolysis</i> , 2015, 39, 60-67.	1.0	27
137	The platelet serotonin release assay. <i>American Journal of Hematology</i> , 2015, 90, 564-572.	2.0	138
138	Pitfalls in the diagnosis of heparin-induced thrombocytopenia: A 6-year experience from a reference laboratory. <i>American Journal of Hematology</i> , 2015, 90, 629-633.	2.0	26
139	Failure of Anticoagulant Thromboprophylaxis. <i>Critical Care Medicine</i> , 2015, 43, 401-410.	0.4	106
140	Ischemic Limb Gangrene with Pulses. <i>New England Journal of Medicine</i> , 2015, 373, 642-655.	13.9	92
141	Rivaroxaban for treatment of HIT: A riveting first experience. <i>Thrombosis Research</i> , 2015, 135, 1-2.	0.8	8
142	HIT complicating fondaparinux prophylaxis: fondaparinux-dependent platelet activation as a marker for fondaparinux-induced HIT. <i>Thrombosis and Haemostasis</i> , 2014, 112, 1319-1322.	1.8	22
143	Anticoagulant failure in coagulopathic patients: PTT confounding and other pitfalls. <i>Expert Opinion on Drug Safety</i> , 2014, 13, 25-43.	1.0	76
144	Design of the rivaroxaban for heparin-induced thrombocytopenia study. <i>Journal of Thrombosis and Thrombolysis</i> , 2014, 38, 485-492.	1.0	29

#	ARTICLE	IF	CITATIONS
145	Immature Platelet Count. <i>Journal of the American College of Cardiology</i> , 2014, 64, 2130-2132.	1.2	8
146	Progressive thrombocytopenia after cardiac surgery in a 67-year-old man. <i>Cmaj</i> , 2014, 186, 929-933.	0.9	29
147	Voting with your fondaparinux. <i>Thrombosis Research</i> , 2014, 134, 3-4.	0.8	4
148	Heparin-induced thrombocytopenia in the critically ill: Interpreting the 4Ts test in a randomized trial. <i>Journal of Critical Care</i> , 2014, 29, 470.e7-470.e15.	1.0	44
149	Platelet Microparticle Generation Assay for Detection of HIT Antibodies: Advance, Retreat, or Too Soon to Tell?. <i>Thrombosis Research</i> , 2014, 133, 957-958.	0.8	6
150	An Instrument-based Immunoassay with an Appropriate Normal Range: Minimizing HIT Overdiagnosis. <i>Thrombosis Research</i> , 2014, 133, 961-962.	0.8	0
151	Serological investigation of patients with a previous history of heparin-induced thrombocytopenia who are reexposed to heparin. <i>Blood</i> , 2014, 123, 2485-2493.	0.6	74
152	Spontaneous heparin-induced thrombocytopenia syndrome: 2 new cases and a proposal for defining this disorder. <i>Blood</i> , 2014, 123, 3651-3654.	0.6	132
153	Fc β 1a proteolysis as a diagnostic biomarker for heparin-induced thrombocytopenia. <i>Journal of Thrombosis and Haemostasis</i> , 2013, 11, 1146-1153.	1.9	14
154	Approach to the Diagnosis and Management of Drug-Induced Immune Thrombocytopenia. <i>Transfusion Medicine Reviews</i> , 2013, 27, 137-145.	0.9	141
155	A systematic evaluation of laboratory testing for drug-induced immune thrombocytopenia. <i>Journal of Thrombosis and Haemostasis</i> , 2013, 11, 169-176.	1.9	109
156	Anti-PF4/heparin antibodies and venous graft occlusion in postcoronary artery bypass surgery patients randomized to postoperative unfractionated heparin or fondaparinux thromboprophylaxis. <i>Journal of Thrombosis and Haemostasis</i> , 2013, 11, 253-260.	1.9	14
157	Anti-protamine-heparin antibodies: incidence, clinical relevance, and pathogenesis. <i>Blood</i> , 2013, 121, 2821-2827.	0.6	64
158	Thrombocytopenia in Critically Ill Patients Receiving Thromboprophylaxis. <i>Chest</i> , 2013, 144, 1207-1215.	0.4	171
159	Heparin-Induced Thrombocytopenia in Medical Surgical Critical Illness. <i>Chest</i> , 2013, 144, 848-858.	0.4	60
160	Improving Clinical Interpretation of the Anti-Platelet Factor 4/Heparin Enzyme-Linked Immunosorbent Assay for the Diagnosis of Heparin-Induced Thrombocytopenia Through the Use of Receiver Operating Characteristic Analysis, Stratum-Specific Likelihood Ratios, and Bayes Theorem. <i>Chest</i> , 2013, 144, 1269-1275.	0.4	63
161	Transient pseudothrombocytopenia associated with immune heparin-induced thrombocytopenia complicated by pulmonary embolism. <i>Thrombosis and Haemostasis</i> , 2013, 109, 971-973.	1.8	5
162	Spontaneous Heparin-Induced Thrombocytopenia Syndrome: Two New Cases and a Proposal For Defining This Disorder. <i>Blood</i> , 2013, 122, 2328-2328.	0.6	1

#	ARTICLE	IF	CITATIONS
163	Combination Of 4Tâ€™s Score and Rapid Gel Centrifugation Assay Excludes HIT In a Prospective Cohort Study. <i>Blood</i> , 2013, 122, 3535-3535.	0.6	1
164	Acute Hepatic Necrosis and Ischemic Limb Necrosis. <i>New England Journal of Medicine</i> , 2012, 367, 879-881.	13.9	21
165	HIT: treatment easier, prevention harder. <i>Blood</i> , 2012, 119, 1099-1100.	0.6	11
166	Aspirin for Dual Prevention of Venous and Arterial Thrombosis. <i>New England Journal of Medicine</i> , 2012, 367, 2039-2041.	13.9	46
167	Predictive value of the 4Ts scoring system for heparin-induced thrombocytopenia: a systematic review and meta-analysis. <i>Blood</i> , 2012, 120, 4160-4167.	0.6	393
168	Hemodialysis-Associated Acute Systemic Reactions and Heparin-Induced Thrombocytopenia. <i>Thrombosis Research</i> , 2012, 129, 405-406.	0.8	5
169	The serological profile of fondaparinux-associated heparin-induced thrombocytopenia syndrome. <i>Thrombosis and Haemostasis</i> , 2012, 108, 394-396.	1.8	25
170	Recombinant factor VIIa (rFVIIa) and hemodialysis to manage massive dabigatran-associated postcardiac surgery bleeding. <i>Blood</i> , 2012, 119, 2172-2174.	0.6	219
171	Optical Densities Reduce Odds of Heparin-induced Thrombocytopenia Over-diagnosis. <i>American Journal of Medicine</i> , 2012, 125, 3-4.	0.6	185
172	Heparin-Induced Thrombocytopenia in the ICU. <i>Chest</i> , 2012, 142, 815-816.	0.4	17
173	The serological profile of early-onset and persisting post-cardiac surgery thrombocytopenia complicated by â€œtrueâ€ heparin-induced thrombocytopenia. <i>Thrombosis and Haemostasis</i> , 2012, 107, 998-1000.	1.8	7
174	Prognostic importance of preoperative anti-PF4/heparin antibodies in patients undergoing cardiac surgery. <i>Thrombosis and Haemostasis</i> , 2012, 107, 8-14.	1.8	14
175	Intraoperative anticoagulation and limb amputations in patients with immune heparin-induced thrombocytopenia who require vascular surgery. <i>Journal of Thrombosis and Haemostasis</i> , 2012, 10, 148-150.	1.9	15
176	Storage of thawed plasma for a liquid plasma bank: impact of temperature and methylene blue pathogen inactivation. <i>Transfusion</i> , 2012, 52, 529-536.	0.8	24
177	The effect of blood storage duration on in-hospital mortality: a randomized controlled pilot feasibility trial. <i>Transfusion</i> , 2012, 52, 1203-1212.	0.8	61
178	Old blood bad? Either the biggest issue in transfusion medicine or a nonevent. <i>Transfusion</i> , 2012, 52, 1165-1167.	0.8	3
179	A prospective study measuring the development of antibodies against platelet factor 4-heparin in healthy males after exposure to heparins. <i>Journal of Thrombosis and Haemostasis</i> , 2012, 10, 1446-1449.	1.9	8
180	HITlights: A career perspective on heparin-induced thrombocytopenia. <i>American Journal of Hematology</i> , 2012, 87, S92-9.	2.0	48

#	ARTICLE	IF	CITATIONS
181	Reversing Anticoagulant Therapy. <i>Current Drug Discovery Technologies</i> , 2012, 9, 143-149.	0.6	8
182	Heparin-Induced Thrombocytopenia in Critically Ill Patients. <i>Critical Care Clinics</i> , 2011, 27, 805-823.	1.0	39
183	Combined use of the high heparin step and optical density to optimize diagnostic sensitivity and specificity of an anti-PF4/heparin enzyme-immunoassay. <i>Thrombosis Research</i> , 2011, 128, 256-260.	0.8	35
184	Prospective multicentre cohort study of heparin-induced thrombocytopenia in acute ischaemic stroke patients. <i>British Journal of Haematology</i> , 2011, 154, 378-386.	1.2	13
185	The association between platelet activation and Fc γ R1la proteolysis. <i>Journal of Thrombosis and Haemostasis</i> , 2011, 9, 885-887.	1.9	7
186	Fondaparinux treatment of acute heparin-induced thrombocytopenia confirmed by the serotonin release assay: a 30-month, 16-patient case series. <i>Journal of Thrombosis and Haemostasis</i> , 2011, 9, 2389-2396.	1.9	127
187	Laboratory testing for heparin-induced thrombocytopenia: a conceptual framework and implications for diagnosis. <i>Journal of Thrombosis and Haemostasis</i> , 2011, 9, 2498-2500.	1.9	150
188	HIT paradigms and paradoxes. <i>Journal of Thrombosis and Haemostasis</i> , 2011, 9, 105-117.	1.9	88
189	PROphylaxis for ThromboEmbolism in Critical Care Trial protocol and analysis plan. <i>Journal of Critical Care</i> , 2011, 26, 223.e1-223.e9.	1.0	24
190	Randomized trial of fondaparinux versus heparin to prevent graft failure after coronary artery bypass grafting: the Fonda CABG study. <i>Journal of Thrombosis and Thrombolysis</i> , 2011, 32, 378-385.	1.0	14
191	Venous limb gangrene and fatal hemorrhage: Adverse consequences of hit overdiagnosis in a patient with antiphospholipid syndrome. <i>American Journal of Hematology</i> , 2011, 86, 188-191.	2.0	26
192	Chills and limb pain following administration of low-molecular-weight heparin for treatment of acute venous thromboembolism. <i>American Journal of Hematology</i> , 2011, 86, 603-606.	2.0	11
193	Heparin-Induced Thrombocytopenia: Real-World Issues. <i>Seminars in Thrombosis and Hemostasis</i> , 2011, 37, 653-663.	1.5	53
194	A Novel Sickling Hemoglobinopathy. <i>New England Journal of Medicine</i> , 2011, 365, 1548-1549.	13.9	5
195	Dalteparin versus Unfractionated Heparin in Critically Ill Patients. <i>New England Journal of Medicine</i> , 2011, 364, 1305-1314.	13.9	382
196	How I Diagnose and Manage HIT. <i>Hematology American Society of Hematology Education Program</i> , 2011, 2011, 143-149.	0.9	129
197	Impact of laboratory testing for heparin-induced antibodies: using Bayes' rule to prevent overdiagnosis of heparin-induced thrombocytopenia/Bedeutung von Laboruntersuchungen von Heparin-induzierten Antikörpern: Einsatz des Bayes Wahrscheinlichkeitstheorems zur Prävention der Überdiagnose einer Heparin-induzierten Thrombozytopenie. <i>Laboratoriums Medizin</i> . 2011, 35. 45-54.	0.1	0
198	Prevalence and Risk of Preexisting Heparin-Induced Thrombocytopenia Antibodies in Patients With Acute VTE. <i>Chest</i> , 2011, 140, 366-373.	0.4	69

#	ARTICLE	IF	CITATIONS
199	Identifying Drugs Implicated in Drug-Induced Immune Thrombocytopenia Using Levels of Evidence Applied to Laboratory Tests. <i>Blood</i> , 2011, 118, 3304-3304.	0.6	0
200	Combination immunosuppressant therapy for patients with chronic refractory immune thrombocytopenic purpura. <i>Blood</i> , 2010, 115, 29-31.	0.6	65
201	HIT: more than just heparin. <i>Blood</i> , 2010, 115, 1664-1665.	0.6	9
202	DITP causation: 3 methods better than 1?. <i>Blood</i> , 2010, 116, 2002-2003.	0.6	5
203	Fondaparinux thromboprophylaxis-associated heparin-induced thrombocytopenia syndrome complicated by arterial thrombotic stroke. <i>Thrombosis and Haemostasis</i> , 2010, 104, 1071-1072.	1.8	44
204	The 4Ts scoring system for heparin-induced thrombocytopenia in medical-surgical intensive care unit patients. <i>Journal of Critical Care</i> , 2010, 25, 287-293.	1.0	117
205	Studies of the anti-platelet factor 4/heparin immune response: adapting the enzyme-linked immunosorbent spot assay for detection of memory B cells against complex antigens. <i>Transfusion</i> , 2010, 50, 32-39.	0.8	30
206	Posttransfusion platelet count increments after ABO-compatible versus ABO-incompatible platelet transfusions in noncancer patients: an observational study. <i>Transfusion</i> , 2010, 50, 1552-1560.	0.8	42
207	Transfusion premedication to prevent acute transfusion reactions: a retrospective observational study to assess current practices. <i>Transfusion</i> , 2010, 50, 1722-1730.	0.8	29
208	Early-onset and persisting thrombocytopenia in post-cardiac surgery patients is rarely due to heparin-induced thrombocytopenia, even when antibody tests are positive. <i>Journal of Thrombosis and Haemostasis</i> , 2010, 8, 30-36.	1.9	157
209	The use of well-characterized sera for the assessment of new diagnostic enzyme-immunoassays for the diagnosis of heparin-induced thrombocytopenia. <i>Journal of Thrombosis and Haemostasis</i> , 2010, 8, 216-218.	1.9	40
210	Anti-PF4/heparin antibody formation postorthopedic surgery thromboprophylaxis: the role of non-drug risk factors and evidence for a stoichiometry-based model of immunization. <i>Journal of Thrombosis and Haemostasis</i> , 2010, 8, 504-512.	1.9	51
211	Non-necrotizing heparin-induced skin lesions and the 4T TM s score. <i>Journal of Thrombosis and Haemostasis</i> , 2010, 8, 1483-1485.	1.9	62
212	Heparin-induced thrombocytopenia: towards standardization of platelet factor 4/heparin antigen tests. <i>Journal of Thrombosis and Haemostasis</i> , 2010, 8, 2025-2031.	1.9	74
213	Transient Global Amnesia as the Presenting Feature of Heparin-Induced Thrombocytopenia. <i>Journal of Cardiac Surgery</i> , 2010, 25, 300-302.	0.3	14
214	Regression Analysis with a Misclassified Covariate from a Current Status Observation Scheme. <i>Biometrics</i> , 2010, 66, 415-425.	0.8	2
215	Heyde TM s syndrome: From controversy to mainstream. <i>Thrombosis and Haemostasis</i> , 2010, 103, 251-253.	1.8	10
216	Agents for the Treatment of Heparin-Induced Thrombocytopenia. <i>Hematology/Oncology Clinics of North America</i> , 2010, 24, 755-775.	0.9	65

#	ARTICLE	IF	CITATIONS
217	Incidence and clinical relevance of anti-platelet factor 4/heparin antibodies before cardiac surgery. <i>American Heart Journal</i> , 2010, 160, 362-369.	1.2	43
218	Fondaparinux: does it cause HIT? can it treat HIT?. <i>Expert Review of Hematology</i> , 2010, 3, 567-581.	1.0	81
219	Heparin-induced anaphylactic and anaphylactoid reactions: two distinct but overlapping syndromes. <i>Expert Opinion on Drug Safety</i> , 2009, 8, 129-144.	1.0	95
220	Adverse Prognostic Significance of Thrombocytopenia in Acute Coronary Syndrome. <i>Circulation</i> , 2009, 119, 2420-2422.	1.6	11
221	Managing bleeding in anticoagulated patients with a focus on novel therapeutic agents. <i>Journal of Thrombosis and Haemostasis</i> , 2009, 7, 107-110.	1.9	98
222	Suboptimal effect of a three-factor prothrombin complex concentrate (Profilnine [®] SD) in correcting supratherapeutic international normalized ratio due to warfarin overdose. <i>Transfusion</i> , 2009, 49, 1171-1177.	0.8	172
223	Immune mechanisms in heparin-induced thrombocytopenia: no evidence for immunoglobulin M anti-idiotypic antibodies. <i>Transfusion</i> , 2009, 49, 1812-1818.	0.8	4
224	Current perspective of venous thrombosis in the upper extremity: a rebuttal. <i>Journal of Thrombosis and Haemostasis</i> , 2009, 7, 237-238.	1.9	7
225	Heparin-induced thrombocytopenia (HIT) during postoperative warfarin thromboprophylaxis: a second example of postorthopedic surgery "spontaneous" HIT. <i>Journal of Thrombosis and Haemostasis</i> , 2009, 7, 499-501.	1.9	50
226	Antiphospholipid and anti-PF4 antibodies: an association affecting anti-PF4/heparin assay analysis. <i>Journal of Thrombosis and Haemostasis</i> , 2009, 7, 1067-1069.	1.9	7
227	Immunoassays are not created equal. <i>Journal of Thrombosis and Haemostasis</i> , 2009, 7, 1256-1259.	1.9	21
228	The paradox of heparin-induced thrombocytopenia. <i>Journal of Thrombosis and Haemostasis</i> , 2009, 7, 1472-1473.	1.9	5
229	Heparin-Induced Thrombocytopenia in Patients with Ventricular Assist Devices: Are New Prevention Strategies Required?. <i>Annals of Thoracic Surgery</i> , 2009, 87, 1633-1640.	0.7	72
230	The temporal profile of the anti-PF4/heparin immune response. <i>Blood</i> , 2009, 113, 4970-4976.	0.6	109
231	Studies of the immune response in heparin-induced thrombocytopenia. <i>Blood</i> , 2009, 113, 4963-4969.	0.6	157
232	Inter-Rater Reliability of the 4Ts Scoring System for Diagnosing Heparin-Induced Thrombocytopenia in Critically Ill Patients.. <i>Blood</i> , 2009, 114, 3995-3995.	0.6	2
233	Analysis of a nonsusceptible fraction with current status data. <i>Statistics in Medicine</i> , 2008, 27, 2715-2730.	0.8	9
234	Delayed-onset HIT caused by low-molecular-weight heparin manifesting during fondaparinux prophylaxis. <i>American Journal of Hematology</i> , 2008, 83, 876-878.	2.0	39

#	ARTICLE	IF	CITATIONS
235	Heparin-induced thrombocytopenia in patients requiring prolonged intensive care unit treatment after cardiopulmonary bypass. <i>Journal of Thrombosis and Haemostasis</i> , 2008, 6, 428-435.	1.9	74
236	Can heparin-induced thrombocytopenia be associated with fondaparinux use? Reply to a rebuttal. <i>Journal of Thrombosis and Haemostasis</i> , 2008, 6, 1243-1246.	1.9	32
237	Quantitative interpretation of optical density measurements using PF4-dependent enzyme immunoassays. <i>Journal of Thrombosis and Haemostasis</i> , 2008, 6, 1304-1312.	1.9	333
238	Fatal heparin-induced thrombocytopenia (HIT) during warfarin thromboprophylaxis following orthopedic surgery: another example of "spontaneous" HIT?. <i>Journal of Thrombosis and Haemostasis</i> , 2008, 6, 1598-1600.	1.9	70
239	An algorithm for resolving "indeterminate" test results in the platelet serotonin release assay for investigation of heparin-induced thrombocytopenia. <i>Journal of Thrombosis and Haemostasis</i> , 2008, 6, 1595-1597.	1.9	24
240	Heparin-induced thrombocytopenia " therapeutic concentrations of danaparoid, unlike fondaparinux and direct thrombin inhibitors, inhibit formation of platelet factor 4-heparin complexes. <i>Journal of Thrombosis and Haemostasis</i> , 2008, 6, 2160-2167.	1.9	68
241	Formation of anti-platelet factor 4/heparin antibodies after cardiac surgery: Influence of perioperative platelet activation, the inflammatory response, and histocompatibility leukocyte antigen status. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2008, 136, 1456-1463.	0.4	20
242	A Spontaneous Prothrombotic Disorder Resembling Heparin-induced Thrombocytopenia. <i>American Journal of Medicine</i> , 2008, 121, 632-636.	0.6	154
243	Heparin-induced thrombocytopenia: A stoichiometry-based model to explain the differing immunogenicities of unfractionated heparin, low-molecular-weight heparin, and fondaparinux in different clinical settings. <i>Thrombosis Research</i> , 2008, 122, 211-220.	0.8	105
244	Risk of heparin-induced thrombocytopenia in patients receiving thromboprophylaxis. <i>Expert Review of Hematology</i> , 2008, 1, 75-85.	1.0	31
245	Contaminated Heparin. <i>New England Journal of Medicine</i> , 2008, 359, 1291-1293.	13.9	21
246	The Approach to Heparin-Induced Thrombocytopenia. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2008, 29, 066-074.	0.8	37
247	Bleeding risk and the management of bleeding complications in patients undergoing anticoagulant therapy: focus on new anticoagulant agents. <i>Blood</i> , 2008, 111, 4871-4879.	0.6	260
248	Heparin-induced thrombocytopenia: a historical perspective. <i>Blood</i> , 2008, 112, 2607-2616.	0.6	172
249	The direct thrombin inhibitor hirudin. <i>Thrombosis and Haemostasis</i> , 2008, 99, 819-829.	1.8	207
250	Bivalirudin. <i>Thrombosis and Haemostasis</i> , 2008, 99, 830-839.	1.8	211
251	Treatment and Prevention of Heparin-Induced Thrombocytopenia. <i>Chest</i> , 2008, 133, 340S-380S.	0.4	783
252	Confirmatory procedure and other maneuvers to assess pathogenicity of platelet factor 4 (PF4)-dependent antibodies " distinguishing "signal" from "noise". <i>Thrombosis and Haemostasis</i> , 2008, 100, 523-524.	1.8	14

#	ARTICLE	IF	CITATIONS
253	Acute pancreatitis preceding thrombotic thrombocytopenic Purpura. <i>Haematologica</i> , 2007, 92, e94-e95.	1.7	10
254	Drug-Induced Immune-Mediated Thrombocytopenia – From Purpura to Thrombosis. <i>New England Journal of Medicine</i> , 2007, 356, 891-893.	13.9	161
255	Heparin-induced thrombocytopenia in intensive care patients. <i>Critical Care Medicine</i> , 2007, 35, 1165-1176.	0.4	179
256	Who Is (Still) Getting HIT?. <i>Chest</i> , 2007, 131, 1620-1622.	0.4	28
257	So, Does Low-Molecular-Weight Heparin Cause Less Heparin-Induced Thrombocytopenia Than Unfractionated Heparin or Not?. <i>Chest</i> , 2007, 132, 1108-1110.	0.4	22
258	When is HIT Really HIT?. <i>Annals of Thoracic Surgery</i> , 2007, 83, 21-23.	0.7	32
259	Heparin-Induced Thrombocytopenia Associated with Fondaparinux. <i>New England Journal of Medicine</i> , 2007, 356, 2653-2655.	13.9	265
260	Heparin-Induced Thrombocytopenia. <i>Hematology/Oncology Clinics of North America</i> , 2007, 21, 589-607.	0.9	83
261	Laboratory testing for heparin-induced thrombocytopenia is inconsistent in North America: A survey of North American specialized coagulation laboratories. <i>Thrombosis and Haemostasis</i> , 2007, 98, 1357-1361.	1.8	60
262	Delayed-onset heparin-induced thrombocytopenia, venous thromboembolism, and cerebral venous thrombosis: A consequence of heparin – flushes. <i>Thrombosis and Haemostasis</i> , 2007, 98, 1139-1140.	1.8	39
263	What is the potential for overdiagnosis of heparin-induced thrombocytopenia?. <i>American Journal of Hematology</i> , 2007, 82, 1037-1043.	2.0	209
264	PF4-dependent immunoassays and inferential detection of HIT antibodies. <i>Journal of Thrombosis and Haemostasis</i> , 2007, 5, 232-234.	1.9	7
265	Clinical sample investigation (CSI) hematology: pinpointing the precise onset of heparin-induced thrombocytopenia (HIT). <i>Journal of Thrombosis and Haemostasis</i> , 2007, 5, 636-637.	1.9	17
266	Heparin-induced thrombocytopenia: a prospective study on the incidence, platelet-activating capacity and clinical significance of antiplatelet factor 4/heparin antibodies of the IgG, IgM, and IgA classes. <i>Journal of Thrombosis and Haemostasis</i> , 2007, 5, 1666-1673.	1.9	224
267	Performance characteristics of a rapid assay for anti-PF4/heparin antibodies: the particle immunofiltration assay. <i>Journal of Thrombosis and Haemostasis</i> , 2007, 5, 2308-2310.	1.9	38
268	Case report: Management of immediate post-cardiopulmonary bypass massive intra-cardiac thrombosis. <i>Canadian Journal of Anaesthesia</i> , 2007, 54, 461-466.	0.7	16
269	History of Heparin-Induced Thrombocytopenia. <i>Fundamental and Clinical Cardiology</i> , 2007, , 1-20.	0.0	2
270	Clinical Picture of Heparin-Induced Thrombocytopenia. <i>Fundamental and Clinical Cardiology</i> , 2007, , 21-66.	0.0	29

#	ARTICLE	IF	CITATIONS
271	Frequency of Heparin-Induced Thrombocytopenia. <i>Fundamental and Clinical Cardiology</i> , 2007, , 67-116.	0.0	20
272	Pseudo-Heparin-Induced Thrombocytopenia. <i>Fundamental and Clinical Cardiology</i> , 2007, , 261-282.	0.0	6
273	Treatment of Heparin-Induced Thrombocytopenia: An Overview. <i>Fundamental and Clinical Cardiology</i> , 2007, , 283-318.	0.0	6
274	Incidence of HPA-9b in Testing for Neonatal Alloimmune Thrombocytopenia.. <i>Blood</i> , 2007, 110, 3214-3214.	0.6	0
275	Results of a systematic evaluation of treatment outcomes for heparin-induced thrombocytopenia in patients receiving danaparoid, ancrod, and/or coumarin explain the rapid shift in clinical practice during the 1990s. <i>Thrombosis Research</i> , 2006, 117, 507-515.	0.8	66
276	Gender imbalance and risk factor interactions in heparin-induced thrombocytopenia. <i>Blood</i> , 2006, 108, 2937-2941.	0.6	259
277	Lepirudin: walking the dosing line. <i>Blood</i> , 2006, 108, 1428-1429.	0.6	2
278	Think of HIT When Thrombosis Follows Heparin. <i>Chest</i> , 2006, 130, 631-632.	0.4	16
279	Heparin-induced thrombocytopenia in the critical care setting: Diagnosis and management^. <i>Critical Care Medicine</i> , 2006, 34, 2898-2911.	0.4	84
280	No significant improvement in diagnostic specificity of an anti-PF4/polyanion immunoassay with use of high heparin confirmatory procedure. <i>Journal of Thrombosis and Haemostasis</i> , 2006, 4, 281-282.	1.9	43
281	Evaluation of pretest clinical score (4 T's) for the diagnosis of heparin-induced thrombocytopenia in two clinical settings. <i>Journal of Thrombosis and Haemostasis</i> , 2006, 4, 759-765.	1.9	916
282	Thrombocytopenia associated with the use of GPIIb/IIIa inhibitors: position paper of the ISTH working group on thrombocytopenia and GPIIb/IIIa inhibitors. <i>Journal of Thrombosis and Haemostasis</i> , 2006, 4, 678-679.	1.9	62
283	Should vitamin K be administered when HIT is diagnosed after administration of coumarin?. <i>Journal of Thrombosis and Haemostasis</i> , 2006, 4, 894-896.	1.9	36
284	Testing for Heparin-Induced Thrombocytopenia Antibodies. <i>Transfusion Medicine Reviews</i> , 2006, 20, 259-272.	0.9	142
285	HIT: Lessons Learned. <i>Pathophysiology of Haemostasis and Thrombosis: International Journal on Haemostasis and Thrombosis Research</i> , 2006, 35, 50-57.	0.5	25
286	Think of HIT. <i>Hematology American Society of Hematology Education Program</i> , 2006, 2006, 408-414.	0.9	75
287	Close Approximation of Two Platelet Factor 4 Tetramers by Charge Neutralization Forms the Antigens Recognized by HIT Antibodies. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2006, 26, 2386-2393.	1.1	156
288	An Algorithm for Indeterminate Test Results in the Platelet Serotonin Release Assay for Heparin-Induced Thrombocytopenia (HIT).. <i>Blood</i> , 2006, 108, 1048-1048.	0.6	0

#	ARTICLE	IF	CITATIONS
289	New Approaches to the Diagnosis of Heparin-Induced Thrombocytopenia. <i>Chest</i> , 2005, 127, 35S-45S.	0.4	145
290	Effect of fondaparinux on platelet activation in the presence of heparin-dependent antibodies: a blinded comparative multicenter study with unfractionated heparin. <i>Blood</i> , 2005, 105, 139-144.	0.6	196
291	Replacement of unfractionated heparin by low-molecular-weight heparin for postorthopedic surgery antithrombotic prophylaxis lowers the overall risk of symptomatic thrombosis because of a lower frequency of heparin-induced thrombocytopenia. <i>Blood</i> , 2005, 106, 2921-2922.	0.6	94
292	Antiplatelet factor 4/heparin antibodies in orthopedic surgery patients receiving antithrombotic prophylaxis with fondaparinux or enoxaparin. <i>Blood</i> , 2005, 106, 3791-3796.	0.6	271
293	Laboratory testing for the antibodies that cause heparin-induced thrombocytopenia: How much class do we need?. <i>Translational Research</i> , 2005, 146, 341-346.	2.4	261
294	Thrombocytopenia in medical-surgical critically ill patients: prevalence, incidence, and risk factors. <i>Journal of Critical Care</i> , 2005, 20, 348-353.	1.0	210
295	Immune heparin-induced thrombocytopenia can occur in patients receiving clopidogrel and aspirin. <i>American Journal of Hematology</i> , 2005, 78, 188-192.	2.0	25
296	Clinical features of heparin-induced thrombocytopenia including risk factors for thrombosis. <i>Thrombosis and Haemostasis</i> , 2005, 94, 132-135.	1.8	352
297	Differences in the clinically effective molar concentrations of four direct thrombin inhibitors explain their variable prothrombin time prolongation. <i>Thrombosis and Haemostasis</i> , 2005, 94, 958-964.	1.8	130
298	Heparin-Induced Skin Lesions and Other Unusual Sequelae of the Heparin-Induced Thrombocytopenia Syndrome. <i>Chest</i> , 2005, 127, 1857-1861.	0.4	121
299	Heparin, Low Molecular Weight Heparin, and Heparin-Induced Thrombocytopenia in the ICU. <i>Critical Care Clinics</i> , 2005, 21, 513-529.	1.0	35
300	Bivalirudin: a review. <i>Expert Opinion on Pharmacotherapy</i> , 2005, 6, 1349-1371.	0.9	58
301	Towards a Conceptual Framework for Diagnosis of Heparin-Induced Thrombocytopenia (HIT).. <i>Blood</i> , 2005, 106, 1234-1234.	0.6	1
302	An Overview of the Heparin-Induced Thrombocytopenia Syndrome. <i>Seminars in Thrombosis and Hemostasis</i> , 2004, 30, 273-283.	1.5	106
303	Heparin-Induced Thrombocytopenia. <i>Circulation</i> , 2004, 110, e454-8.	1.6	165
304	Heparin-Induced Thrombocytopenia: Recognition, Treatment, and Prevention. <i>Chest</i> , 2004, 126, 311S-337S.	0.4	766
305	Hypotensive transfusion reactions can occur with blood products that are leukoreduced before storage. <i>Transfusion</i> , 2004, 44, 1361-1366.	0.8	41
306	Warfarin-associated multiple digital necrosis complicating heparin-induced thrombocytopenia and Raynaud's phenomenon after aortic valve replacement for adenocarcinoma-associated thrombotic endocarditis. <i>American Journal of Hematology</i> , 2004, 75, 56-62.	2.0	25

#	ARTICLE	IF	CITATIONS
307	Bivalent direct thrombin inhibitors: hirudin and bivalirudin. <i>Best Practice and Research in Clinical Haematology</i> , 2004, 17, 105-125.	0.7	123
308	Heparin-Induced Thrombocytopenia and Vascular Surgery. <i>Acta Chirurgica Belgica</i> , 2004, 104, 257-265.	0.2	14
309	Argatroban Inhibits Human Factor Xa at Therapeutic Drug Levels: An Explanation for Its Prolongation of the INR.. <i>Blood</i> , 2004, 104, 1845-1845.	0.6	0
310	Gastrointestinal bleeding, angiodysplasia, cardiovascular disease, and acquired von Willebrand syndrome. <i>Transfusion Medicine Reviews</i> , 2003, 17, 272-286.	0.9	171
311	Heparin-induced thrombocytopenia: pathogenesis and management. <i>British Journal of Haematology</i> , 2003, 121, 535-555.	1.2	492
312	Delayed-Onset Heparin-Induced Thrombocytopenia and Cerebral Thrombosis after a Single Administration of Unfractionated Heparin. <i>New England Journal of Medicine</i> , 2003, 348, 1067-1069.	13.9	101
313	Heparin-induced thrombocytopenia and cardiac surgery. <i>Annals of Thoracic Surgery</i> , 2003, 76, 2121-2131.	0.7	638
314	Management of heparin-induced thrombocytopenia: a critical comparison of lepirudin and argatroban. <i>Thrombosis Research</i> , 2003, 110, 73-82.	0.8	107
315	Heparin-induced thrombocytopenia and cardiac surgery. <i>Annals of Thoracic Surgery</i> , 2003, 76, 638-648.	0.7	187
316	An Improved Definition of Immune Heparin-Induced Thrombocytopenia in Postoperative Orthopedic Patients. <i>Archives of Internal Medicine</i> , 2003, 163, 2518.	4.3	287
317	Platelet-Endothelial Interactions: Sepsis, HIT, and Antiphospholipid Syndrome. <i>Hematology American Society of Hematology Education Program</i> , 2003, 2003, 497-519.	0.9	127
318	Prothrombotic genetic risk factors and heparin-induced thrombocytopenia. <i>Pharmacogenetics and Genomics</i> , 2003, 13, 245-246.	5.7	2
319	Central venous catheters and upper-extremity deep-vein thrombosis complicating immune heparin-induced thrombocytopenia. <i>Blood</i> , 2003, 101, 3049-3051.	0.6	164
320	Laboratory diagnosis of immune heparin-induced thrombocytopenia. <i>Psychophysiology</i> , 2003, 2, 148-57.	1.1	150
321	Gastrointestinal Angiodysplasia and Aortic Stenosis. <i>New England Journal of Medicine</i> , 2002, 347, 858-859.	13.9	79
322	Current agents for the treatment of patients with heparin-induced thrombocytopenia. <i>Current Opinion in Pulmonary Medicine</i> , 2002, 8, 405-412.	1.2	23
323	Venous limb gangrene during overlapping therapy with warfarin and a direct thrombin inhibitor for immune heparin-induced thrombocytopenia. <i>American Journal of Hematology</i> , 2002, 71, 50-52.	2.0	95
324	Platelet Count Monitoring and Laboratory Testing for Heparin-Induced Thrombocytopenia. <i>Archives of Pathology and Laboratory Medicine</i> , 2002, 126, 1415-1423.	1.2	124

#	ARTICLE	IF	CITATIONS
325	Reversing anticoagulants both old and new. Canadian Journal of Anaesthesia, 2002, 49, S11-25.	0.7	60
326	Heparin-induced thrombocytopenia and the anesthesiologist. Canadian Journal of Anaesthesia, 2002, 49, S36-49.	0.7	4
327	Heparin-induced thrombocytopenia. Psychophysiology, 2002, 1, 63-72.	1.1	11
328	Argatroban. Drugs, 2001, 61, 523-524.	4.9	3
329	Temporal Aspects of Heparin-Induced Thrombocytopenia. New England Journal of Medicine, 2001, 344, 1286-1292.	13.9	925
330	Decreased von Willebrand factor protease activity associated with thrombocytopenic disorders. Blood, 2001, 98, 1842-1846.	0.6	198
331	Venous Limb Gangrene during Warfarin Treatment of Cancer-Associated Deep Venous Thrombosis. Annals of Internal Medicine, 2001, 135, 589.	2.0	82
332	Delayed-Onset Heparin-Induced Thrombocytopenia and Thrombosis. Annals of Internal Medicine, 2001, 135, 502.	2.0	429
333	Heparin and Low-Molecular-Weight Heparin Mechanisms of Action, Pharmacokinetics, Dosing, Monitoring, Efficacy, and Safety. Chest, 2001, 119, 64S-94S.	0.4	1,275
334	Heparin-induced thrombocytopenia: yet another treatment paradox?. Thrombosis and Haemostasis, 2001, 85, 947-9.	1.8	4
335	Heparin-induced thrombocytopenia and its treatment. Journal of Thrombosis and Thrombolysis, 2000, 9, 29-35.	1.0	16
336	Morphological analysis of microparticle generation in heparin-induced thrombocytopenia. Blood, 2000, 96, 188-194.	0.6	190
337	Impact of the patient population on the risk for heparin-induced thrombocytopenia. Blood, 2000, 96, 1703-1708.	0.6	976
338	Impact of the patient population on the risk for heparin-induced thrombocytopenia. Blood, 2000, 96, 1703-1708.	0.6	22
339	Impact of the patient population on the risk for heparin-induced thrombocytopenia. Blood, 2000, 96, 1703-8.	0.6	150
340	HEPARIN-INDUCED THROMBOCYTOPENIA: A Ten-Year Retrospective. Annual Review of Medicine, 1999, 50, 129-147.	5.0	128
341	A prospective study of protein-specific assays used to investigate idiopathic thrombocytopenic purpura. British Journal of Haematology, 1999, 104, 442-447.	1.2	144
342	Newer Strategies for the Treatment of Heparin-Induced Thrombocytopenia. Pharmacotherapy, 1999, 19, 181-195.	1.2	49

#	ARTICLE	IF	CITATIONS
343	Multicentric warfarin-induced skin necrosis complicating heparin-induced thrombocytopenia. <i>American Journal of Hematology</i> , 1999, 62, 44-48.	2.0	90
344	Generation of platelet-derived microparticles and procoagulant activity by heparin-induced thrombocytopenia IgG/serum and other IgG platelet agonists: a comparison with standard platelet agonists. <i>Platelets</i> , 1999, 10, 319-326.	1.1	52
345	Multicentric warfarin-induced skin necrosis complicating heparin-induced thrombocytopenia. <i>American Journal of Hematology</i> , 1999, 62, 44-48.	2.0	3
346	Heparin-induced thrombocytopenia: a clinicopathologic syndrome. <i>Thrombosis and Haemostasis</i> , 1999, 82, 439-47.	1.8	55
347	Intraoperative Heparin Flushes and Subsequent Acute Heparin-induced Thrombocytopenia. <i>Anesthesiology</i> , 1998, 89, 1567-1569.	1.3	49
348	Heparin-induced thrombocytopenia: towards consensus. <i>Thrombosis and Haemostasis</i> , 1998, 79, 1-7.	1.8	84
349	Clinical presentation of heparin-induced thrombocytopenia. <i>Seminars in Hematology</i> , 1998, 35, 9-16; discussion 35-6.	1.8	140
350	Limitations of conventional treatment options for heparin-induced thrombocytopenia. <i>Seminars in Hematology</i> , 1998, 35, 17-25; discussion 35-6.	1.8	42
351	The Pathogenesis of Venous Limb Gangrene Associated with Heparin-Induced Thrombocytopenia. <i>Annals of Internal Medicine</i> , 1997, 127, 804.	2.0	427
352	The alloimmune thrombocytopenic syndromes. <i>Transfusion Medicine Reviews</i> , 1997, 11, 296-307.	0.9	40
353	Activation of platelets by sera containing igg1 heparin-dependent antibodies: an explanation for the predominance of the FcγRIIIa (his131) gene in patients with heparin-induced thrombocytopenia. <i>Translational Research</i> , 1997, 130, 278-284.	2.4	88
354	PROTEOLYTIC DEGRADATION OF HIGH MOLECULAR WEIGHT KININOGEN IN ACUTE THROMBOTIC THROMBOCYTOPENIC PURPURA. <i>British Journal of Haematology</i> , 1997, 97, 762-767.	1.2	5
355	The alloimmune thrombocytopenic syndromes. <i>Transfusion Medicine Reviews</i> , 1997, 11, 296-307.	0.9	26
356	A 14-year study of heparin-induced thrombocytopenia. <i>American Journal of Medicine</i> , 1996, 101, 502-507.	0.6	872
357	Heparin-induced skin lesions. <i>British Journal of Haematology</i> , 1996, 92, 494-497.	1.2	175
358	Heparin-Induced thrombocytopenia: IgG-Mediated platelet activation, platelet microparticle generation, and altered procoagulant/anticoagulant balance in the pathogenesis of thrombosis and venous limb gangrene complicating heparin-Induced thrombocytopenia. <i>Transfusion Medicine Reviews</i> , 1996, 10, 249-258.	0.9	104
359	Isolation and characterization of cysteine proteinase in thrombotic thrombocytopenic purpura. <i>British Journal of Haematology</i> , 1996, 93, 421-426.	1.2	18
360	The epitope specificity of heparin-induced thrombocytopenia. <i>British Journal of Haematology</i> , 1996, 95, 161-167.	1.2	152

#	ARTICLE	IF	CITATIONS
361	A diagnostic test for heparin-induced thrombocytopenia: detection of platelet microparticles using flow cytometry. <i>British Journal of Haematology</i> , 1996, 95, 724-731.	1.2	125
362	Bacterial infection-associated improvement of platelet counts in two patients with chronic and unresponsive idiopathic thrombocytopenic purpura with normal platelet survival studies. <i>British Journal of Haematology</i> , 1995, 90, 332-335.	1.2	5
363	The prenatal identification of fetal compatibility in neonatal alloimmune thrombocytopenia using amniotic fluid and variable number of tandem repeat (VNTR) analysis. <i>British Journal of Haematology</i> , 1995, 91, 742-746.	1.2	17
364	Heparin-Induced Thrombocytopenia in Patients Treated with Low-Molecular-Weight Heparin or Unfractionated Heparin. <i>New England Journal of Medicine</i> , 1995, 332, 1330-1336.	13.9	2,664
365	Transient global amnesia associated with acute heparin-induced thrombocytopenia. <i>American Journal of Medicine</i> , 1994, 97, 489-491.	0.6	61
366	Sera from patients with heparin-induced thrombocytopenia generate platelet-derived microparticles with procoagulant activity: an explanation for the thrombotic complications of heparin-induced thrombocytopenia. <i>Blood</i> , 1994, 84, 3691-9.	0.6	86
367	Heparin-induced thrombocytopenia and thrombosis: clinical and laboratory studies. <i>British Journal of Haematology</i> , 1993, 84, 322-328.	1.2	175
368	Investigation of human platelet alloantigens and glycoproteins using non-radioactive immunoprecipitation. <i>Journal of Immunological Methods</i> , 1993, 158, 77-85.	0.6	36
369	Aortic stenosis and bleeding gastrointestinal angiodysplasia: is acquired von Willebrand's disease the link?. <i>Lancet</i> , The, 1992, 340, 35-37.	6.3	254
370	Determinants of donor platelet variability when testing for heparin-induced thrombocytopenia. <i>Translational Research</i> , 1992, 120, 371-9.	2.4	124
371	Thrombocytopenia caused by passive transfusion of anti-glycoprotein Ia/IIa alloantibody (anti-HPA-5b). <i>Blood</i> , 1992, 79, 2480-4.	0.6	4
372	Measurement of fibrinogen binding to platelets in whole blood by flow cytometry: a micromethod for the detection of platelet activation. <i>British Journal of Haematology</i> , 1990, 76, 387-394.	1.2	81
373	Current Concepts in the Treatment of Immune Thrombocytopenia. <i>Drugs</i> , 1990, 40, 531-542.	4.9	18
374	Heparin and platelets. <i>Hematology/Oncology Clinics of North America</i> , 1990, 4, 243-64.	0.9	5
375	Heparin-Induced Thrombocytopenia. <i>Annual Review of Medicine</i> , 1989, 40, 31-44.	5.0	112
376	Spinal-cord concussion in frogs a study of reflex changes. <i>World Neurosurgery</i> , 1983, 20, 456-460.	1.3	10
377	Management of Immune Thrombocytopenia. , 0, , 344-375.		3
378	Diagnosis and Management of Heparin-Induced Thrombocytopenia. , 0, , 158-167.		0